Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

BACKGROUND: Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that contains the full-length spike glycoprotein of the prototype strain plus Matrix-M adjuvant, showed that the...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:N Engl J Med
मुख्य लेखकों: Heath, Paul T., Galiza, Eva P., Baxter, David N., Boffito, Marta, Browne, Duncan, Burns, Fiona, Chadwick, David R., Clark, Rebecca, Cosgrove, Catherine, Galloway, James, Goodman, Anna L., Heer, Amardeep, Higham, Andrew, Iyengar, Shalini, Jamal, Arham, Jeanes, Christopher, Kalra, Philip A., Kyriakidou, Christina, McAuley, Daniel F., Meyrick, Agnieszka, Minassian, Angela M., Minton, Jane, Moore, Patrick, Munsoor, Imrozia, Nicholls, Helen, Osanlou, Orod, Packham, Jonathan, Pretswell, Carol H., San Francisco Ramos, Alberto, Saralaya, Dinesh, Sheridan, Ray P., Smith, Richard, Soiza, Roy L., Swift, Pauline A., Thomson, Emma C., Turner, Jeremy, Viljoen, Marianne E., Albert, Gary, Cho, Iksung, Dubovsky, Filip, Glenn, Greg, Rivers, Joy, Robertson, Andreana, Smith, Kathy, Toback, Seth
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Massachusetts Medical Society 2021
विषय:
Original Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC8262625/
https://ncbi.nlm.nih.gov/pubmed/34192426
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2107659
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन